-+ 0.00%
-+ 0.00%
-+ 0.00%

MINK THERAPEUTICS AND UNIVERSITY OF WISCONSIN–MADISON ANNOUNCE PHASE 1 CLINICAL TRIAL OF ALLO-INKT CELL THERAPY (AGENT-797) TO EVALUATE PREVENTION OF GRAFT-VERSUS-HOST DISEASE

Reuters·01/08/2026 17:00:00

Please log in to view news